Sanofi India Limited has announced its 70th Annual General Meeting (AGM), scheduled for Wednesday, April 29, 2026. The company has published its Integrated Annual Report for the financial year ended December 31, 2025. During this fiscal year, Sanofi India recorded a revenue from operations of ₹18,374 million and an EBITDA of ₹5,110 million. The company remains focused on its diabetes portfolio and strategic digital transformation initiatives to drive long-term value.
Financial Highlights
For the financial year 2025, Sanofi India achieved a revenue from operations of ₹18,374 million, with a Profit After Tax (PAT) of ₹3,267 million. The company’s EBITDA for the same period stood at ₹5,110 million. The Board of Directors has recommended a final dividend of ₹48 per equity share, which, when combined with the interim dividend of ₹75 per share, brings the total dividend for the year 2025 to ₹123 per equity share.
Strategic Focus and Operational Achievements
In 2025, Sanofi India successfully sharpened its focus on its diabetes portfolio, which continues to anchor the business with market-leading insulin brands such as Lantus® and Toujeo®. The company has also achieved significant operational milestones, including a 62.4% reduction in total Scope 1 and Scope 2 emissions compared to 2024, and ensuring that 77.5% of energy requirements are met through renewable sources. Furthermore, the Goa manufacturing site maintains a state-of-the-art, GMP-compliant status, supporting both domestic and international markets across 25 countries.
Leadership Transition and AGM Details
The company is undergoing a significant leadership transition, welcoming Mr. Deepak Arora as the new Managing Director. The 70th AGM will be held on April 29, 2026, at 3:30 p.m. (IST) via video conferencing. Members are encouraged to participate in remote e-voting, which commences on April 25, 2026, at 9:00 a.m. and concludes on April 28, 2026, at 5:00 p.m.
Community and ESG Impact
Sanofi India’s commitment to social responsibility remains robust, reaching over 1.8 million CSR beneficiaries during the year. Key initiatives included the KiDS (Kids and Diabetes in Schools) program and the deployment of 21 Mobile Medical Units in Maharashtra, which provided vital NCD screening and healthcare services to underserved communities.
Source: BSE
